A 28-year-old Indian woman presents with fever, sore throat, and widespread atypical targetoid lesions on the face and trunk that have progressed to flaccid bullae with positive Nikolsky sign. Oral mucosa shows hemorrhagic crusting and erosions. She had started carbamazepine 10 days ago for newly diagnosed epilepsy. The clinical diagnosis of Stevens-Johnson Syndrome (SJS) is made. The management pathway marked **A** in the diagram is initiated. Which of the following best describes the PRIMARY RATIONALE for this intervention?

Question

Accepted Answer

A. Immediate cessation of the offending drug reduces mortality by approximately 30% per day saved and is the single most critical intervention in SJS management. ## Why Option 1 is correct

The clinical anchor from Bastuji-Garin et al. and Harrison's 21st edition establishes that **immediate withdrawal of the culprit drug is the SINGLE MOST IMPORTANT intervention** in SJS management, reducing mortality by approximately 30% per day saved. The structure marked **A** — "Stop offending drug, supportive care, ophthalmologic consultation ± IVIG/cyclosporine" — encapsulates this principle. In this case, carbamazepine (a high-risk anticonvulsant, especially during dose escalation) must be stopped immediately. SJS is a severe cutaneous adverse reaction (SCAR) mediated by drug-specific HLA-restricted CD8+ cytotoxic T-cell responses; continued drug exposure perpetuates keratinocyte apoptosis via granulysin, perforin, granzyme B, and FasL. Stopping the drug halts this cascade and is the foundation of all subsequent supportive and immunomodulatory measures.

## Why each distractor is wrong

- **Option 2**: Topical steroids as monotherapy (marked **C**) are insufficient and are NOT first-line management. Systemic immunomodulation (cyclosporine, IVIG) and drug withdrawal are required. Topical agents alone cannot halt the underlying CD8+ T-cell-driven apoptosis.
- **Option 3**: Empirical antiviral therapy (marked **D**) is NOT first-line treatment. While HSV/CMV reactivation and Mycoplasma pneumoniae can trigger SJS, the majority of cases (95%) are drug-induced. Antiviral therapy is not indicated unless a specific infectious trigger is confirmed; the priority is drug withdrawal.
- **Option 4**: Resumption of the offending drug at lower dose (marked **B**) is contraindicated and dangerous. Re-exposure to the culprit drug risks recurrence and worsening of the reaction. All high-risk drugs must be permanently avoided and documented as allergies; HLA typing (e.g., HLA-B*15:02 for carbamazepine in Asians) guides future prescribing.

**High-Yield:** In SJS, **drug withdrawal is more important than any immunosuppressive therapy**—delay in stopping the culprit drug increases mortality by ~30% per day.

[cite: Bastuji-Garin et al. Arch Dermatol 1993; Harrison's Principles of Internal Medicine 21st ed]

Answer

B. Topical corticosteroids alone halt keratinocyte apoptosis and prevent progression to toxic epidermal necrolysis

Answer

C. Resumption of the offending drug at a lower dose allows immune tolerance and prevents recurrence of the reaction

Answer

D. Empirical antiviral therapy targets the underlying Mycoplasma pneumoniae infection present in all SJS cases

Explanation

Why Option 1 is correct

Why each distractor is wrong

Practice similar questions